Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.
Also called NCT02966028
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 274 participants
- Sponsor
- Sanifit Therapeutics S. A.
- Registry
-
NCT02966028
-
- Other papers using this trial's data
- Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study
- Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02966028. Randomized; quadruple masking; primary purpose treatment. Start 2016-11 (registry gives no type); primary completion 2019-08 (actual). Results posted on 2021-03-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
- Condition
- Cardiovascular Diseases
- Condition
- Cardiovascular Abnormalities
- Condition
- Calcifications, Vascular
- Condition
- Endstage Renal Disease
- Condition
- ESRD
- Condition
- Coronary Artery Calcification
- Intervention (Drug)
- SNF472
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sanifit Therapeutics S. A.
- Collaborator
- Clinipace Worldwide
Record details
- Record id
cardio:ct-nct02966028- Content hash
0a997283ef12440a499fc5decfd808b27f79c57dec32369e50f5071a8ade9e7d